Європейський Союз - естонська - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Естонія - естонська - Ravimiamet

fresenius kabi ab - kombinatsioonid - infusiooniemulsioon - 1540ml 4tk; 2053ml 4tk; 2566ml 3tk; 1540ml 1tk; 2053ml 2tk; 2053ml 1tk; 2566ml 2tk

Естонія - естонська - Ravimiamet

fresenius kabi ab - kombinatsioonid - infusiooniemulsioon - 1970ml 4tk; 1477ml 4tk; 2463ml 3tk; 2463ml 2tk; 493ml 1tk; 1477ml 1tk; 986ml 1tk; 986ml 4tk; 493ml 6tk; 1970ml 1tk; 1970ml 2tk

Естонія - естонська - Ravimiamet

fresenius kabi ab - kombinatsioonid - infusiooniemulsioon - 1970ml 4tk; 1477ml 1tk; 493ml 6tk; 986ml 1tk; 2463ml 3tk; 493ml 1tk; 1970ml 1tk; 1970ml 2tk; 2463ml 1tk

Естонія - естонська - Ravimiamet

fresenius kabi ab - kombinatsioonid - infusiooniemulsioon - 1904ml 1tk; 1448ml 1tk; 1448ml 4tk; 1206ml 1tk; 1904ml 4tk; 1904ml 3tk; 1206ml 4tk

Естонія - естонська - Ravimiamet

fresenius kabi ab - kombinatsioonid - infusiooniemulsioon - 1518ml 1tk; 2025ml 1tk; 2531ml 3tk; 2025ml 4tk; 506ml 1tk; 506ml 6tk; 1518ml 4tk; 2531ml 1tk; 1012ml 4tk

Естонія - естонська - Ravimiamet

b. braun melsungen ag - paratsetamool - infusioonilahus - 10mg 1ml 50ml 10tk; 10mg 1ml 100ml 10tk; 10mg 1ml 10ml 20tk

Естонія - естонська - Ravimiamet

fresenius kabi ab - elektrolüüdid - infusioonilahuse kontsentraat - 10ml 20tk

Європейський Союз - естонська - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastilised ained - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Європейський Союз - естонська - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosupressandid - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on näidustatud ravi täiskasvanud patsientidel, kellel on varem ravimata hulgimüeloom, kes ei ole abikõlblikud siirdamist. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).